Analysis of TMEs indicates that combinatorial therapy significantly augments tumor-infiltrating Th9 cells, boosts anti-tumor effects of CD8<sup>+</sup> T cells, and remodels tumor immunosuppressive microenvironments. The gene discussed is CD8A; the disease is neoplasm.